Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET

Company Participants

Stéphane Paquette - VP, Corporate Development
Krish Krishnan - Chairman and CEO
Suma Krishnan - President, Research and Development
Jennifer McDonough - SVP, Patient Access, Analytics and Operations
Christine Wilson - SVP and Head, U.S. Sales and Marketing
Kate Romano - CAO

Conference Call Participants

Alec Stranahan - BOA
Yigal Nochomovitz - Citigroup
Ritu Baral - TD Cowen
Sami Corwin - William Blair
Gavin Clark-Gartner - Evercore ISI
Dae Gon Ha - Stifel
Debjit Chattopadhyay - Guggenheim Securities
Andrea Newkirk - Goldman Sachs

Operator

Thank you for standing by and welcome to Krystal Biotech's Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.

I would now like to hand the conference over to your host, Stéphane Paquette, Vice President of Corporate Development. Please begin.

Stéphane Paquette

Good morning, and thank you all for joining today's call. Earlier today, we released our financial results for the third quarter of 2024. The press release is available on our website at www.krystalbio.com. We also filed our earnings 8-K and 10-Q with the SEC earlier today.

Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Jennifer McDonough, Senior Vice President of Patient Access, Analytics and Operations; Christine Wilson, Senior Vice President and Head of U.S. Sales and Marketing; and Kate Romano, Chief Accounting Officer.

This conference call will and our responses to questions may contain forward-looking statements. You are cautioned not to rely on these forward-looking statements, which are based on current expectations using the information available as of the date of this call and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties, and other factors can be found in our SEC filings.

With that, I will turn the call over to Krish.

Krish Krishnan

Thank you, Stephane. Good morning, and welcome to the call.

Look, as I mentioned in my PR attribution, we're well on our way to achieving the two-year target that we set at the time of the launch. And by comparison to any other launch in orphan diseases or genetic therapies, we believe our launches exceeded all expectations to date. In my mind, there are two primary drivers for this success. The first obviously being the drug itself with all its attributes of efficacy, safety, patient convenience, et cetera. And the second being our assiduous focus on patient and physician experience.